LitCovid-sentences  

PMC:7534795 / 19412-24588 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T115 0-106 Sentence denotes Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference
T116 107-203 Sentence denotes • Tocilizumab for IL-6 cytokine release syndrome • Multicenter Randomized controlled trial (RCT)
T117 204-232 Sentence denotes • Severe COVID-19 infections
T118 233-253 Sentence denotes • 18–85 years of age
T119 254-275 Sentence denotes • Elevated serum IL-6
T120 276-316 Sentence denotes • N = 94 standard therapy + tocilizumab
T121 317-377 Sentence denotes • N = 94 standard therapy • 4–8 mg/kg tocilizumab i.v. once
T122 378-509 Sentence denotes • Additional dose if fever persists in 24 h after first dose • First phase showed normalization of fever within 24 h of tocilizumab
T123 510-615 Sentence denotes • Improved respiratory function, oxygenation, and pulmonary lesions • Phase 4 study completed in May 2020
T124 616-633 Sentence denotes • Results pending
T125 634-783 Sentence denotes • Tocilizumab may be a promising investigative therapy to reduce cytokine release syndrome and associated multi-organ damage (ChiCTR2000029765, 2020)
T126 784-882 Sentence denotes • Tocilizumab to mitigate cytokine storm and associated complications • Retrospective cohort study
T127 883-901 Sentence denotes • >18 years of age
T128 902-954 Sentence denotes • Intensive care unit (ICU) COVID-19 hospitalization
T129 955-1003 Sentence denotes • Primary endpoint of hospital-related mortality
T130 1004-1042 Sentence denotes • N = 210 standard care + tocilizumab
T131 1043-1111 Sentence denotes • N = 420 standard care • 400 mg single dose or 8 mg/kg tocilizumab
T132 1112-1266 Sentence denotes • 88% required 1 infusion, 12% received a second infusion • Hazard ratio (HR) 0.71 for hospital related mortality (95% confidence interval (CI) 0.56–0.89)
T133 1267-1349 Sentence denotes • Treatment was more effective in patients with C-reactive protein (CRP) >15 mg/dL
T134 1350-1560 Sentence denotes • HR 0.48 (95% CI 0.30–0.77) than those with CRP <15 mg/dL HR 0.92 (95% CI 0.57–1.48) • Tocilizumab treatment is associated with a lower rate of mortality, particularly in those with enhanced inflammatory state
T135 1561-1652 Sentence denotes • Double blind RCT recently completed with results pending NCT04320615 (Biran et al., 2020)
T136 1653-1727 Sentence denotes • Tocilizumab to mitigate cytokine storm • Prospective observational study
T137 1728-1767 Sentence denotes • Severe or critical COVID-19 infection
T138 1768-1791 Sentence denotes • 25 to 88 years of age
T139 1792-1832 Sentence denotes • N = 21 tocilizumab + standard therapy
T140 1833-1892 Sentence denotes • 42.9% had CVD • 4–8 mg/kg or 400 mg tocilizumab i.v. once
T141 1893-2021 Sentence denotes • 85.7% received single dose of tocilizumab, 14.3% required second dose within 12 h of first dose • Fever normalized within 24 h
T142 2022-2055 Sentence denotes • Reduced O2 therapy requirements
T143 2056-2092 Sentence denotes • Minimal improvement in IL-6 levels
T144 2093-2121 Sentence denotes • CT lung lesion improvement
T145 2122-2190 Sentence denotes • All patients discharged • Limited sample size and no control group
T146 2191-2314 Sentence denotes • Tocilizumab treatment in severe COVID-19 cases may improve clinical symptoms in hyperinflammatory state (Xu et al., 2020)
T147 2315-2436 Sentence denotes • Intensive methylprednisolone regimen +/− tocilizumab for management of cytokine storm • Prospective observational study
T148 2437-2492 Sentence denotes • O2 sat ≤ 94% OR tachypnea, elevated CRP, high D-dimer
T149 2493-2556 Sentence denotes • Primary outcome of hospital discharge or clinical improvement
T150 2557-2601 Sentence denotes • N = 86 methylprednisolone +/− tocilizumab
T151 2602-2635 Sentence denotes • N = 86 standard care • Stage 1:
T152 2636-2709 Sentence denotes Immediate methylprednisolone 250 mg i.v. on day 1, then 80 mg on days 2–5
T153 2710-2783 Sentence denotes • Stage 2 (lack of clinical improvement or worsening respiratory status):
T154 2784-2897 Sentence denotes Add tocilizumab 8 mg/kg i.v. once between days 2–5 • Improvement in respiratory status HR 1.79 (95% CI 1.20–2.67)
T155 2898-2949 Sentence denotes • Improvement reached in a shorter time vs. control
T156 2950-3178 Sentence denotes • Reduced hospital mortality and need for mechanical ventilation • Short duration of intensive immunosuppressive therapy is associated with improved clinical outcomes in patients with hyperinflammaory state (Ramiro et al., 2020)
T157 3179-3275 Sentence denotes • Ruxolitinib treatment for elevated cytokine levels and inflammatory response • Prospective RCT
T158 3276-3321 Sentence denotes • 18 to 75 years of age with severe infection
T159 3322-3371 Sentence denotes • Primary outcome of time to clinical improvement
T160 3372-3409 Sentence denotes • N = 20 ruxolitinib + standard care
T161 3410-3474 Sentence denotes • N = 21 placebo + standard care • Ruxolitinib 5 mg twice daily
T162 3475-3579 Sentence denotes • Placebo vitamin C 100 mg twice daily • No difference in primary endpoint HR 1.669 (95% CI 0.836–3.335)
T163 3580-3636 Sentence denotes • Improvement in lung computerized tomography (CT) scans
T164 3637-3806 Sentence denotes • Significantly reduced cytokine levels and CRP by day 3 • Ruxolitinib may hasten time of chest CT scan improvement and mitigate systemic inflammation (Cao et al., 2020)
T165 3807-3912 Sentence denotes • Anakinra for targeting the cytokine inflammatory cascade through IL-1 blockade • Open label case series
T166 3913-3933 Sentence denotes • Elevated CRP N = 9
T167 3934-3981 Sentence denotes • 6/9 with CVD risk factors (diabetes, obesity)
T168 3982-4051 Sentence denotes • 3/9 with hypertension • Anakinra 100 mg every 12 h s.c. on days 1–3
T169 4052-4124 Sentence denotes • Anakinra 100 mg once daily s.c. on days 4–10 • Fever subsided by day 3
T170 4125-4165 Sentence denotes • CRP normalized in 5 patients by day 11
T171 4166-4205 Sentence denotes • Halted progression of CT lung lesions
T172 4206-4276 Sentence denotes • 100% survival • Small case series, potential for confounding factors
T173 4277-4327 Sentence denotes • Potential therapy to target inflammatory cascade
T174 4328-4424 Sentence denotes • Positive results in patients with hypertension and other CVD risk factors (Aouba et al., 2020)
T175 4425-4442 Sentence denotes • Ana-COVID study
T176 4443-4531 Sentence denotes • Anakinra for COVID-19 hyperinflammatory state • Prospective/retrospective cohort study
T177 4532-4581 Sentence denotes • Hospitalized adults with critical lung function
T178 4582-4635 Sentence denotes • Cohort with CVD (hypertension, stroke, cardiopathy)
T179 4636-4707 Sentence denotes • Primary outcome of ICU admission with mechanical ventilation or death
T180 4708-4742 Sentence denotes • N = 52 anakinra + standard care
T181 4743-4812 Sentence denotes • N = 44 standard care • Anakinra 100 mg s.c. twice daily for 3 days
T182 4813-5105 Sentence denotes • Then anakinra 100 mg s.c. once daily for 7 days • Significantly reduced need for mechanical ventilation or death HR 0.22 (0.11–0.41) • Anakinra may be associated with improved outcomes in patients with severe COVID-19 infection, including those with CVD and history of cardiovascular events
T183 5106-5176 Sentence denotes • May be due to mitigation of inflammatory cascade (Huet et al., 2020)